论文部分内容阅读
目的探讨辛伐他汀预防介入治疗术后冠心病慢性心力衰竭患者再狭窄及改善心功能的作用。方法随机将行介入治疗的250例冠心病慢性心力衰竭患者分为两组各125例,观察组术后应用辛伐他汀40～80mg强化降脂治疗,对照组给予辛伐他汀20mg常规剂量降脂治疗治疗。对两组随访12个月,观察两组左室射血分数、血脂指标变化情况及再狭窄发生率等。结果术后随访12个月后观察组LVEF、各血脂指标均较对照组差异有统计学意义(P﹤0.05);观察组再狭窄率为2.4%(3/125),明显低于对照组8.0%(10/125)(χ2=4.31,P﹤0.05)。用药期间两组肝肾功、心肌酶谱无明显异常。结论辛伐他汀能有效改善介入术后的冠心病合并慢性心衰患者心功能及血脂指标,并具有预防冠脉再狭窄功能。
Objective To investigate the effect of simvastatin on preventing restenosis and improving cardiac function in patients with chronic heart failure after coronary intervention. Methods A total of 250 CHD patients with chronic heart failure who underwent interventional therapy were randomly divided into two groups of 125 cases. The observation group was treated with simvastatin 40 ~ 80 mg, the control group was given simvastatin 20 mg conventional dose Treatment and treatment. The two groups were followed up for 12 months, observed left ventricular ejection fraction, blood lipid changes and restenosis rates. Results After 12 months of follow-up, the LVEF and the indexes of blood lipids in the observation group were significantly different from those in the control group (P <0.05). The restenosis rate in the observation group was 2.4% (3/125), significantly lower than that of the control group % (10/125) (χ2 = 4.31, P <0.05). During the two groups of liver and kidney function, myocardial enzyme no obvious abnormalities. Conclusion Simvastatin can effectively improve cardiac function and blood lipid in patients with coronary heart disease complicated with chronic heart failure after intervention, and has the function of preventing coronary restenosis.